Diagnocure Inc (DGCRF) 0.0853 $DGCRF
DiagnoCure announces fourth quarter 2014 and year-end results
CNW Group - Fri Jan 23, 6:30AM CST
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"
today reported financial and operational results for the fourth quarter 2014 and fiscal year ended October 31, 2014. The Corporation announced a net loss of $461,710 or $0.01 per share for the fourth quarter ended October 31, 2014, compared to $1,334,099 or $0.03 per share for the same period in 2013 and a net loss of $2,032,151 or $0.05 per share for fiscal year 2014 compared to $3,566,942 or $0.08 per share for the same period in 2013. At the end of the quarter, cash and short-term investments stood at $2,227,326 compared to $4,190,296 at the end of fiscal year 2013.
CUR.TO: 0.11 (unch)
Diagnocure Reports on Corporate Initiatives for 2014
PR Newswire - Thu Oct 30, 4:01PM CDT
Opportunities Being Developed While the Situation with the PCA3 Prostate Cancer Test is Being Resolved
CUR.TO: 0.11 (unch)
DiagnoCure announces results for third quarter of 2014
PR Newswire - Thu Sep 11, 4:01PM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation" today reported financial and operational results for the third quarter 2014 ended July 31, 2014. The Corporation announced a net loss of $504,105 or $0.01 per share for this quarter compared with a loss of $595,262 or $0.01 per share for the same period last year. During the third quarter ended July 31, 2014, total revenues decreased by 19% compared with the same quarter of 2013, due to a decrease in PCA3 royalties paid to DiagnoCure. Operating expenses decreased by $127,318 or 16%, to $657,529 for the third quarter of 2014 from $784,847 for the same period of 2013. At the end of the quarter, cash and short-term investments stood at $2,541,852.
CUR.TO: 0.11 (unch)
DiagnoCure announces fourth quarter 2014 and year-end results
CNW Group - Fri Jan 23, 6:30AM CST
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"
today reported financial and operational results for the fourth quarter 2014 and fiscal year ended October 31, 2014. The Corporation announced a net loss of $461,710 or $0.01 per share for the fourth quarter ended October 31, 2014, compared to $1,334,099 or $0.03 per share for the same period in 2013 and a net loss of $2,032,151 or $0.05 per share for fiscal year 2014 compared to $3,566,942 or $0.08 per share for the same period in 2013. At the end of the quarter, cash and short-term investments stood at $2,227,326 compared to $4,190,296 at the end of fiscal year 2013. CUR.TO: 0.11 (unch)
Diagnocure Reports on Corporate Initiatives for 2014
PR Newswire - Thu Oct 30, 4:01PM CDT
Opportunities Being Developed While the Situation with the PCA3 Prostate Cancer Test is Being Resolved
CUR.TO: 0.11 (unch)
DiagnoCure announces results for third quarter of 2014
PR Newswire - Thu Sep 11, 4:01PM CDT
DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"
today reported financial and operational results for the third quarter 2014 ended July 31, 2014. The Corporation announced a net loss of $504,105 or $0.01 per share for this quarter compared with a loss of $595,262 or $0.01 per share for the same period last year. During the third quarter ended July 31, 2014, total revenues decreased by 19% compared with the same quarter of 2013, due to a decrease in PCA3 royalties paid to DiagnoCure. Operating expenses decreased by $127,318 or 16%, to $657,529 for the third quarter of 2014 from $784,847 for the same period of 2013. At the end of the quarter, cash and short-term investments stood at $2,541,852. CUR.TO: 0.11 (unch)
